Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

Apyx Medical Corporation

We are investigating Apyx Medical Corporation (APYX) (“Apyx” or the “Company”) for potential violations of the federal securities laws. 

On April 1, 2019, Apyx announced that it was voluntarily withdrawing its application for regulatory clearance of its J-Plasma/Renuvion for use in dermal resurfacing procedures, citing an investigational device exemption study that failed to meet the primary efficacy endpoint.  On this news,Apyx’s stock price fell sharply during intraday trading on April 2, 2019.